DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Riastap (Fibrinogen Human) - Summary



RiaSTAP is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma.

RiaSTAP™, Fibrinogen Concentrate (Human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

RiaSTAP is not indicated for dysfibrinogenemia.

See all Riastap indications & dosage >>


Media Articles Related to Riastap (Fibrinogen Human)

Dabigatran associated with higher incidence of major bleeding vs. warfarin
Source: Blood / Hematology News From Medical News Today [2014.11.03]
A study of Medicare beneficiaries suggests the anticoagulant medication dabigatran should be prescribed with caution because it appears to be associated with a higher incidence of major bleeding...

Vaginal Bleeding
Source: MedicineNet Alternative Treatments for Hot Flashes Specialty [2014.07.22]
Title: Vaginal Bleeding
Category: Diseases and Conditions
Created: 7/4/2001 12:00:00 AM
Last Editorial Review: 7/22/2014 12:00:00 AM

Blood in the Stool (Rectal Bleeding)
Source: MedicineNet Anal Fissure Specialty [2014.07.16]
Title: Blood in the Stool (Rectal Bleeding)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/16/2014 12:00:00 AM

Bleeding Gums
Source: MedicineNet Dengue Fever Specialty [2014.05.05]
Title: Bleeding Gums
Category: Symptoms and Signs
Created: 3/8/2010 5:02:00 PM
Last Editorial Review: 5/5/2014 12:00:00 AM

Bleeding Ulcer Symptoms and Causes
Source: MedicineNet Helicobacter Pylori Specialty [2014.04.25]
Title: Bleeding Ulcer Symptoms and Causes
Category: Doctor's & Expert's views on Symptoms
Created: 4/3/2009 12:00:00 AM
Last Editorial Review: 4/25/2014 12:00:00 AM

more news >>

Published Studies Related to Riastap (Fibrinogen Human)

An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. [2012]
The aims were to determine the effect of an oral inhibitor of the signaling mediator p38 mitogen-activated protein kinase (GW856553, losmapimod) on sputum neutrophils, pulmonary function, and blood biomarkers of inflammation in chronic obstructive pulmonary disease (COPD)... It was concluded that oral losmapimod significantly reduced plasma fibrinogen in patients with COPD.

The fibrinogen cleavage product Aalpha-Val360, a specific marker of neutrophil elastase activity in vivo. [2011.08]
BACKGROUND: Alpha-1-antitrypsin (A1AT) deficiency is the only recognised genetic risk factor for chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality worldwide. Since A1AT is the major inhibitor of neutrophil elastase (NE), this enzyme has become widely implicated in the pathogenesis of COPD in general; however, there is currently no specific biomarker for its pre-inhibition activity. Such a biomarker should be a measure of elastase-specific COPD disease activity with the potential to assess early targeted therapeutic intervention, in contrast to traditional and non-specific disease severity markers such as forced expiratory volume in 1 s... CONCLUSIONS: Aalpha-Val(360) represents the first specific footprint of pre-inhibition NE activity and is a potential biomarker of disease activity and progression in subjects with elastase-dependent COPD. TRIAL REGISTRATION: The EXACTLE study was registered in ClinicalTrials.gov as 'Antitrypsin (AAT) to Treat Emphysema in AAT-Deficient Patients'; ClinicalTrials.gov Identifier: NCT00263887.

De Marco Formula effectiveness as an adjunctive therapy to prevent infected ischemic diabetic foot amputation and reduce plasma fibrinogen. [2011.05]
BACKGROUND: De Marco Formula (DMF) is a new procaine chemical combination of Procaine HCl and polyvinylpyrrolidone. A prospective randomized controlled clinical trial demonstrated that infected ischemic diabetic foot treatment with DMF for 52 days as an adjuvant with conventional therapy reduced major amputations. OBJECTIVE: To evaluate the possible association of clinical effectiveness and plasma fibrinogen reduction with DMF therapy... CONCLUSION: DMF combined with conventional therapy for infected ischemic diabetic foot was associated with plasma fibrinogen decrease. Copyright (c) 2010 Tissue Viability Society. Published by Elsevier Ltd. All rights reserved.

Association between gamma' fibrinogen levels and inflammation. [2011.04]
The gamma' fibrinogen isoform produces clots that are stiffer and more resistant to breakdown than the more common fibrinogen isoform, gammaA. Increased levels of gamma' fibrinogen are associated with several forms of cardiovascular disease...

Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study. [2011]
OBJECTIVE: To evaluate thromboelastographic parameters and fibrinogen levels in women treated with transdermal 17beta estradiol... CONCLUSIONS: Our data suggested that transdermal estrogen may not increase blood coagulability, but that it reduces fibrinogen levels in HT women.

more studies >>

Clinical Trials Related to Riastap (Fibrinogen Human)

Fibrinogen Concentrate (Human) − Efficacy and Safety Study [Recruiting]
This is a multinational, multicenter, prospective, open-label historically controlled Phase IIIb non-inferiority clinical trial on the efficacy and safety of Fibrinogen Concentrate (Human).

It is estimated that 150-300 patients in the U. S. suffer from afibrinogenemia. Substitution with cryoprecipitate or alternative treatments have limited safety and efficacy.

The primary purpose of the study is to demonstrate the hemostatic efficacy of Fibrinogen Concentrate (Human) by adequately controlling acute bleeding (spontaneous or after trauma) in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia). Cryoprecipitate hemostatic efficacy data from a retrospective physician survey will be used as a historical control.

Haemocomplettan® P During Aortic Replacement [Recruiting]
The primary purpose is to show that administration of Haemocomplettan® P significantly reduces the amount of blood products needed during aortic surgery.

more trials >>

Page last updated: 2014-11-03

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014